Clinical trials: Aggressive Behaviour
Agitation and Aggression in Alzheimer's Disease
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment
- Trial name
- NCT02992132
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 56 sites in United States, Chile and 3 more
- Volunteers
- 111 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Impulsive Aggression, ADHD
Dialectical Behavioral Therapy Skills for Impulsive Aggression
This trial aims to Study the efficacy of DBT skills for impulsive aggression and executive dysfunctions in drug naïve children who are presented with impulsive aggression and ADHD and attending Child and adolescent clinic at…
- Conditions
- Impulsive Aggression, ADHD, Executive Dysfunction
- Trial name
- NCT05351944
- Testing
- Dialectical behavioral therapy skills for the intervention experimental group A, psychoeducation or Atomoxetine or stimulants according to ADHD severity
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Generalized Aggressive Periodontitis
Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families.
Generalized aggressive periodontitis (GAP) is an inflammatory disease that causes the severe and rapid destruction of periodontal tissue.
- Trial name
- NCT03642353
- Testing
- Triclosan
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Depression, Anxiety
Efficacy of a Multi-level School Intervention for LGBTQ Youth
Efficacy of a Multi-level School Intervention for LGBTQ Youth
- Conditions
- Depression, Anxiety, Post Traumatic Stress Disorder, Coping Behavior
- Trial name
- NCT05541406
- Testing
- Proud & Empowered, Control Group
- Where
- 23 sites in United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphoma, Non-Hodgkin's
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
- Trial name
- NCT00413036
- Testing
- lenalidomide
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 217 people
- Sponsor
- Celgene
Atherosclerosis, Coronary Artery Disease
ARISE - Aggressive Reduction of Inflammation Stops Events
To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events.
- Conditions
- Atherosclerosis, Coronary Artery Disease, Myocardial Infarction, Unstable Angina
- Trial name
- NCT00066898
- Testing
- AGI-1067
- Where
- 219 sites in United States, Canada and 2 more
- Volunteers
- 6,000 people
- Sponsor
- AtheroGenics
Prostate Cancer
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
In Europe, prostate cancer (PCa) is the most common solid neoplasm, with an incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer.
- Trial name
- NCT01672411
- Where
- Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
Aggression, Intellectual Disability
Reducing Aggression Among People With an Intellectual Disability
The study is an randomised controlled trial (RCT) to test whether supplementation of vitamins, minerals and n-3 fatty acids may reduce aggressive behavior in people with intellectual disabilities.
- Trial name
- PSYVB (NCT03212092)
- Testing
- Multivitamin, mineral & n-3 FA
- Where
- 7 sites in Netherlands
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00052936
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 174 sites in Germany, Switzerland
- Volunteers
- 1,506 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies.
- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome
- Trial name
- NCT05665530
- Testing
- PRT2527, Zanubrutinib, Venetoclax
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Aggression
Virtual Reality Training for Aggression Control
The main goal of this randomized controlled trial is to investigate the effectiveness of VR-TRAC (Virtual Reality TRaining for Aggression Control) for reducing aggression in a prison-based population.
- Trial name
- NCT06047587
- Testing
- VR-TrAC, Care as Usual
- Where
- Netherlands
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Alzheimer's Disease
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
- Trial name
- NCT01766336
- Testing
- Group 1 ELND005, Group 2 ELND005
- Where
- 46 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- OPKO Health, Inc.
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable
- Trial name
- NCT03704714
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Lymphoma
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, oxaliplatin, and , work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01307592
- Testing
- rituximab, gemcitabine hydrochloride, lenalidomide
- Where
- Puerto Rico
- Volunteers
- 70 people
- Sponsor
- Auxilio Mutuo Cancer Center
Desmoid Tumor
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects of imatinib mesylate and to see how well it works…
- Trial name
- NCT00287846
- Testing
- imatinib mesylate
- Where
- 23 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Leukemia, Lymphoma
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive…
- Trial name
- NCT00884286
- Testing
- Aplidin®
- Where
- 12 sites in France, Italy and 4 more
- Volunteers
- 67 people
- Sponsor
- PharmaMar
Bullying, Bullying Victimisation
The Effect of the Self-compassion Development Program on Bullying and Victimization in Middle School Students
Violence in schools is an important public health problem affecting the health and safety of schools. Peer bullying, which is a common form of school violence, is defined as the behaviour of a bully person or group that…
- Trial name
- NCT06656910
- Testing
- Self Compassion Group
- Where
- Turkey (Türkiye)
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Marmara University
Thyroid Cancer
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
This study plans to learn more about a drug called bexarotene for the treatment of advanced thyroid cancer. Subjects are asked to be in this study because they have thyroid cancer that will not respond to radioactive iodine…
- Trial name
- NCT00718770
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Meningioma
Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study
The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and/or cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.
- Trial name
- BIOLIMEN-1 (NCT07398170)
- Testing
- Blood sampling, Lumbar puncture
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier